Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04914000
Other study ID # MCC-19733
Secondary ID 1R03CA227044-01A
Status Completed
Phase N/A
First received
Last updated
Start date June 14, 2021
Est. completion date June 2, 2022

Study information

Verified date February 2023
Source H. Lee Moffitt Cancer Center and Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess feasibility and acceptability of an intervention designed to increase smoking cessation motivation among patients with a cancer not widely known to be smoking related.


Recruitment information / eligibility

Status Completed
Enrollment 53
Est. completion date June 2, 2022
Est. primary completion date April 13, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Smoking at least 1 cigarette in previous 30 days - Diagnosis of breast, colorectal, gynecological, skin melanoma, or bladder cancer within the last 6 months - Able to read/write English - Able to give informed consent - Not currently enrolled in a smoking cessation program Exclusion Criteria: - Having distant metastases - Male patients with breast cancer

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Self-help Materials
Self-help booklet targeted by cancer type to increase smoking cessation motivation

Locations

Country Name City State
United States Moffitt Cancer Center Tampa Florida

Sponsors (2)

Lead Sponsor Collaborator
H. Lee Moffitt Cancer Center and Research Institute National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Who Consent to Participate in the Study- Feasibility Number of participants who consent to participate in the study Baseline
Primary Number of Participants That Complete 1-week Follow-up Assessments - Feasibility Number of participants who complete 1-week follow-up assessments 1-week post-treatment
Primary Number of Participants That Complete 1 Month Follow-up Assessments - Feasibility Number of participants who complete 1-month follow-up assessments 1-month post-treatment
Primary Number of Participants Who Read the Booklet - Demand - 1 Week Post Treatment Number of study participants who read the booklet 1-week post-treatment
Primary Number of Participants Who Read the Booklet - Demand - 1 Month Post Treatment Number of study participants who read the booklet 1-month post-treatment
Primary Acceptability Treatment satisfaction measured with 8 items adapted from the Client Satisfaction Questionnaire, values between 8 and 32, with higher scores mean a better outcome. 1-month post-treatment
Secondary Motivation to Quit Smoking Assessed With the Contemplation Ladder Changes in motivation to quit smoking will be assessed using the Contemplation Ladder. This is a validated measure for the assessment of readiness to quit smoking on a scale from 0 to 10. Higher scores indicate greater motivation to quit smoking. Baseline, 1-week post-treatment, 1-month post-treatment
Secondary Motivation to Quit Smoking Assessed With the Short Form of the Smoking Abstinence-related Motivational Engagement (ARME). Changes in motivation to quit smoking will be assessed using the short form of the smoking abstinence-related motivational engagement (ARME), which is a valid and reliable measure of cessation motivation that includes 5 items related to the smokers' daily experience with scores ranging from 5 to 35. Higher scores indicate greater motivation to quit smoking. Baseline, 1-week post-treatment, 1-month post-treatment
Secondary Participants Change in Motivation - Action Stage Changes in motivation to quit smoking will be assessed using the Stages of Change algorithm (SOC). This is a widely used measure for the assessment of readiness to quit smoking. Baseline, at 1 week and 1 month post treatment
Secondary Motivation to Quit Smoking Assessed With the Number of Visits to the Study Website A personal code will be able to track the number of participants who visited the study website where participants will find existing smoking cessation resources. This will be considered a behavioral indicator of motivation to quit smoking. 1-month post-treatment
Secondary Motivation to Quit Smoking Assessed by Contact With the Tobacco Treatment Specialist - 1 Week Participants will be asked if they have contacted the tobacco treatment specialist or if they would like us to make a referral for them. This will be considered a behavioral indicator of motivation to quit smoking. At 1 Week Post Treatment
Secondary Motivation to Quit Smoking Assessed by Contact With the Tobacco Treatment Specialist - 1 Month Participants will be asked if they have contacted the tobacco treatment specialist or if they would like us to make a referral for them. This will be considered a behavioral indicator of motivation to quit smoking. At 1 Month Post Treatment
Secondary Participants That Had a Quit Attempt - 1 Week Number of participants that had a quit attempt that lasted at least 24 hours (at the 1-week assessment) At 1 Week Post Treatment
Secondary Participants That Had a Quit Attempt - 1 Month Number of participants that had a quit attempt that lasted at least 24 hours At 1 Month Post Treatment
Secondary Motivation to Quit Smoking Assessed With the Number of Quit Attempts - 1 Month Number of times participants quit smoking in the last 30 days (at the 1-month assessment). At 1 Month Post Treatment
Secondary Number of Participants Reporting 7-day Point Prevalence Abstinence Smoking abstinence will be determined by a self-report of not smoking in the last 7 days 1-week post-treatment
Secondary Number of Participants Reporting 30-day Point Prevalence Abstinence Smoking abstinence will be determined by a self-report of not smoking in the last 30 days 1-month post-treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases